17国国家药物政策的系统评价

目的系统评价和分析17国国家药物政策的主要内容，为建立适合我国国情的国家药物政策提供决策依据。方法共检索13个电子数据库、WHO、世界银行和17国药品管理相关网站，用预先设计的数据提取表收集相关信息，根据设计的理论框架对提取的信息进行分析和描述。结果共纳人17个国家的182篇文献，各国药物政策共同关注的要点是：药品规制和质量保障、合理用药、药品供应、基本药物遴选、人力资源开发与培训、传统医药、药品筹资和可支付能力、药品研究、药物政策的监测和评估、技术合作和本国医药产业发展：我国在药物遴选、质量保障、供应、定价及传统医药等方面开展工作，而对药品研究、政策监测、本国医药发展和技术合作方面还有待进一步加强：结论建议筹备相关组织机构和规范工作程序，推动国家基本药物政策相关立法工作，健全基本药物目录的遴选机制和配套实施政策，整顿药品生产流通秩序，建立科学合理的药品定价机制和基本药物可及性评估体系，加强药物政策的监测与评估，适时更新和完善国家药物政策。

A Systematic Review of National Drug Policy in Seventeen Countries

Objectives To analyze the development and implementation of the national drug policy in order to provide decision-making for the establishment of the Chinese national drug policy. Methods Nineteen electronic databases, the WHO, the World Bank, and governmental websites were included in this study. A pre-designed data extraction form was used to collect information. The data were analyzed and described by a pre-designed analytic framework+ Result A total of 182 studies were included in this review. The main points of common concern in the national drug policy were: drug regulation and quality assurance, rational use of drugs, drug supply, the selection of essential drugs, human resource development and training, traditional medicine, drug financing and affordability, drug research, monitoring and assessment of the nation drug policy, technical cooperation, and the national pharmaceutical industry. The selection of essential drugs, quality assurance, supply, pricing, and supply of traditional medicine weregradually carried out in China. Pharmaceutical research, monitoring and evaluation, as well as the development of pharmaceutical industry and technical cooperation within it should be further strengthened. Conclusion China should establish related organizations and working procedures; speed up the implementation of the legislation of national drug policy; integrate the mechanism of essential drugs selection and supply system; regulate the order of medicine production and regulation; establish scientific and reasonable pricing mechanisms for drugs and assessment systems; strengthen themonitoring and evaluation of national drug policy and update and improve the national drug policy.